Interestingly, IL-6 has already been selected as the target and a phase 2 randomized, placebo controlled trial of Tocilizumab (targeting IL-6) in ALS patients is currently in data analysis stage. This evidence concerns the gene IL6 and amyotrophic lateral sclerosis.